A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Mercaptamine (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARE-CF-1; CARE-CF2
- Sponsors NovaBiotics
- 24 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
- 24 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.
- 10 Jun 2017 Biomarkers information updated